Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus POLYCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus POLYCILLIN.
OMNIPEN (AMPICILLIN) vs POLYCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Polycillin (ampicillin) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
250-500 mg orally every 6 hours or 500 mg intravenously every 4-6 hours for moderate to severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
Terminal elimination half-life is 0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in anuria.
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Renal excretion of unchanged drug accounts for 60-80% via glomerular filtration and tubular secretion; 20-40% is hepatically metabolized and eliminated in bile/feces.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic